Singapore, 17 October 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the appointment of Ben Goodger as General Counsel. Mr Goodger will assume the role on 1 November 2016 and will be based at ASLAN’s headquarters in Singapore.
Mr Goodger joins ASLAN’s senior management team from multinational law firm Osborne Clarke, where he was until recently Partner and Head of Intellectual Property (IP) Licensing and Transactions in the United Kingdom. Mr Goodger has significant experience in Asia where, based in Shanghai, he ran his previous firm’s China business and Asia commercial IP groups. He is a global IP expert who brings to ASLAN over 20 years of experience in advising corporations on the commercialisation, protection and strategic management of their IP and information technology assets.
Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said, “I am delighted to welcome Ben to our team at a time ASLAN is undergoing tremendous growth. Ben is well acquainted with ASLAN, having worked with us over the past few years on our inlicensing and outlicensing transactions. As ASLAN continues its work in developing novel immunotherapies and agents, Ben’s extensive experience in licensing and intellectual property will be invaluable, and his corporate experience will further strengthen our governance.”
A past president of the Licensing Executives Society of Great Britain and Ireland, Mr Goodger has been ranked as a ‘Legal Expert’ in IP and IT in Legal Business, and has also been recognised by Intellectual Asset Management in its ‘IAM Licensing 250: The World’s Leading Patent and Technology Licensing Practitioners’ list. Mr Goodger is a graduate of Oxford University (Exhibitioner, Keble College).
